Article Text

PDF
Review: formoterol increases serious adverse events in children and adults with chronic asthma

Statistics from Altmetric.com

QUESTION

In patients with chronic asthma, what are the risks of mortality and non-fatal serious adverse events associated with formoterol?

REVIEW SCOPE

Included studies compared inhaled formoterol once or twice daily for ⩾12 weeks with placebo or short-acting β2 agonists in children and adults with chronic asthma. Leukotriene receptor antagonists, inhaled or oral corticosteroids, or theophylline were allowed if they were not part of the randomised intervention. Outcomes were all-cause mortality and all-cause non-fatal serious adverse events.

REVIEW METHODS

Cochrane Airways Group Specialised Register of trials (to Jul 2008), reference lists, clinical trial register websites, and Federal Drug Administration submissions were searched for randomised controlled trials (RCTs). 22 RCTs (n = 8032; weighted mean duration of 16 wks for 19 placebo-controlled RCTs) were included.

MAIN RESULTS

All-cause mortality: formoterol v placebo (14 RCTs, n = 5463). All-cause mortality did …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.